Shin Nippon Biomedical Laboratories, Ltd. (JP:2395) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Shin Nippon Biomedical Laboratories’ subsidiary, Satsuma Pharmaceuticals, has resubmitted its New Drug Application for STS101, a treatment for acute migraine, to the FDA, addressing previous concerns about formulation while receiving no requests for additional clinical trials. This move is seen as pivotal in offering new options for migraine sufferers.
For further insights into JP:2395 stock, check out TipRanks’ Stock Analysis page.